United Therapeutics Corporation UTHR
577.34 USD -6.76 (-1.16%)
Regular-session close
577.34 0.00 0.00%
After hours · Nov 18, 6:19 PM ET
569.34 Day range 588.43
455.63 52-week range 614.23
- YTD
- +18.49%
- 1 year
- +21.14%
News
seekingalpha.com United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
marketbeat.com United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a…
zacks.com SGIOY or UTHR: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).
seekingalpha.com United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
defenseworld.net 5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC Fisher Asset Management LLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 15.2% during the third quarter, according to the company in its most recent disclosure with the…
benzinga.com Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.56% on an annualized basis producing an average annual return of 19.5%. Currently, United Therapeutics has a…benzinga.com HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660 HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.
benzinga.com TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700 TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.
benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $725 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $697 to $725.
benzinga.com Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703 Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
benzinga.com BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768 BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.
benzinga.com United Therapeutics Amends Agreement With Arena Pharmaceuticals, Pfizer Subsidiary, Eliminating All Royalty Obligations Under Its Exclusive License Agreement Related to Ralinepag for an Upfront Payment of $525M This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions Varda says one SpaceX flight could produce drug crystals capable of supporting medicine for millions of patients.benzinga.com JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695 JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
benzinga.com $100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
benzinga.com United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
benzinga.com Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…benzinga.com Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725 Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
benzinga.com The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
